source
- Roche reports phase 3 success for sefaxersen in IgA nephropathy, eyes accelerated approvalRoche announced that its experimental drug sefaxersen met the primary endpoint in a phase 3 trial for IgA nephropathy, showing reduced proteinuria versus placebo. The interim analysis at week 37 d…
- China’s $522 bn biotech push fuels US competition and partnership opportunitiesChinese biotech is entering a rapid growth phase, with the government’s new five-year plan targeting about $522 billion in revenue by 2030 and aiming for at least 25% of first-in-class drugs worldw…